WO2001052874A3 - Intra-tumoral administration of il-12 encoding nucleic acid molecules - Google Patents

Intra-tumoral administration of il-12 encoding nucleic acid molecules Download PDF

Info

Publication number
WO2001052874A3
WO2001052874A3 PCT/EP2001/000363 EP0100363W WO0152874A3 WO 2001052874 A3 WO2001052874 A3 WO 2001052874A3 EP 0100363 W EP0100363 W EP 0100363W WO 0152874 A3 WO0152874 A3 WO 0152874A3
Authority
WO
WIPO (PCT)
Prior art keywords
intra
nucleic acid
acid molecules
encoding nucleic
tumoral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/000363
Other languages
French (fr)
Other versions
WO2001052874A9 (en
WO2001052874A2 (en
Inventor
Karin Moelling
Jan Schultz
Lucie Heinzerling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Priority to JP2001552921A priority Critical patent/JP2003525222A/en
Priority to AT01911481T priority patent/ATE305801T1/en
Priority to DE60113805T priority patent/DE60113805T2/en
Priority to EP01911481A priority patent/EP1248654B1/en
Priority to AU40508/01A priority patent/AU4050801A/en
Publication of WO2001052874A2 publication Critical patent/WO2001052874A2/en
Priority to US10/181,794 priority patent/US7141550B2/en
Publication of WO2001052874A3 publication Critical patent/WO2001052874A3/en
Anticipated expiration legal-status Critical
Publication of WO2001052874A9 publication Critical patent/WO2001052874A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Described is the use of a nucleic acid molecule encoding an IL-12 polypeptide for the preparation of a pharmaceutical composition for the treatment of a tumor, wherein the pharmaceutical composition is for intra-tumoral administration.
PCT/EP2001/000363 2000-01-20 2001-01-12 Intra-tumoral administration of il-12 encoding nucleic acid molecules Ceased WO2001052874A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001552921A JP2003525222A (en) 2000-01-20 2001-01-12 Intratumoral administration of a nucleic acid molecule encoding IL-12
AT01911481T ATE305801T1 (en) 2000-01-20 2001-01-12 INTRATUMORAL ADMINISTRATION OF NAKED IL-12 ENCODING NUCLEIC ACID MOLECULES
DE60113805T DE60113805T2 (en) 2000-01-20 2001-01-12 Intratumoral administration of naked IL-12-encoding nucleic acid molecules
EP01911481A EP1248654B1 (en) 2000-01-20 2001-01-12 Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
AU40508/01A AU4050801A (en) 2000-01-20 2001-01-12 Intra-tumoral administration of il-12 encoding nucleic acid molecules
US10/181,794 US7141550B2 (en) 2000-01-20 2001-12-01 Intra-tumoral administration of IL-12 encoding nucleic acid molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00101108 2000-01-20
EP00101108.9 2000-01-20

Publications (3)

Publication Number Publication Date
WO2001052874A2 WO2001052874A2 (en) 2001-07-26
WO2001052874A3 true WO2001052874A3 (en) 2001-12-20
WO2001052874A9 WO2001052874A9 (en) 2003-05-30

Family

ID=8167670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/000363 Ceased WO2001052874A2 (en) 2000-01-20 2001-01-12 Intra-tumoral administration of il-12 encoding nucleic acid molecules

Country Status (8)

Country Link
US (1) US7141550B2 (en)
EP (1) EP1248654B1 (en)
JP (1) JP2003525222A (en)
AT (1) ATE305801T1 (en)
AU (1) AU4050801A (en)
DE (1) DE60113805T2 (en)
ES (1) ES2246314T3 (en)
WO (1) WO2001052874A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE305801T1 (en) 2000-01-20 2005-10-15 Univ Zuerich Inst Fuer Medizin INTRATUMORAL ADMINISTRATION OF NAKED IL-12 ENCODING NUCLEIC ACID MOLECULES
PL2251034T3 (en) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (en) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glycoproteins and recombinant vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766035B1 (en) 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai NEWCASTLE DISEASE VIRUSES AND USES THEREOF
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108064176A (en) 2015-04-22 2018-05-22 库瑞瓦格股份公司 Compositions containing RNA for the treatment of tumor diseases
WO2017083291A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
JP2019519516A (en) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド MRNA combination therapy for the treatment of cancer
SI3458083T1 (en) * 2016-05-18 2023-03-31 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
CN109715205A (en) * 2016-08-19 2019-05-03 库瑞瓦格股份公司 RNA use for cancer treatment
TW202428301A (en) 2017-02-28 2024-07-16 法商賽諾菲公司 Therapeutic rna
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP7285220B2 (en) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CN111701012A (en) * 2017-09-07 2020-09-25 康立泰药业有限公司 Application of IL-12 in postoperative antitumor aspect
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE305801T1 (en) 2000-01-20 2005-10-15 Univ Zuerich Inst Fuer Medizin INTRATUMORAL ADMINISTRATION OF NAKED IL-12 ENCODING NUCLEIC ACID MOLECULES
JP4147724B2 (en) * 2000-06-09 2008-09-10 ソニー株式会社 ANTENNA DEVICE AND RADIO DEVICE

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BUDRYK MAGDALENA ET AL: "Direct transfer of IL-12 gene into growing Renca tumors.", ACTA BIOCHIMICA POLONICA, vol. 47, no. 2, 2000, pages 385 - 391, XP002170597, ISSN: 0001-527X *
CANCER GENE THERAPY, (2000) 7/12 (1557-1565). *
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 45, no. 2, October 1997 (1997-10-01), pages 100 - 108, ISSN: 0340-7004 *
CHU R S ET AL: "CPG OLIGODEOXYNUCLEOTIDES ACT AS ADJUVANTS THAT SWITCH ON T HELPER 1 (TH1) IMMUNITY", JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO, vol. 186, no. 10, 1 November 1997 (1997-11-01), pages 1623 - 1631, XP002910130, ISSN: 0022-1007 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 September 2000 (2000-09-01), MENDIRATTA SANJEEV K ET AL: "Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.", XP002170604, Database accession no. PREV200000436961 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 10 February 1999 (1999-02-10), SCHULTZ JAN ET AL: "Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA.", XP000215681, Database accession no. PREV199900145697 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, YANG J -P ET AL: "Direct gene transfer to mouse melanoma by intratumor injection of free DNA.", XP002170601, Database accession no. PREV199699090602 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), ASSELIN-PATUREL C ET AL: "Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography.", XP002170600, Database accession no. PREV199900227212 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1998 (1998-11-01), MULLINS DAVID W ET AL: "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation.", XP002170603, Database accession no. PREV199800513263 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1997 (1997-10-01), LASEK WITOLD ET AL: "Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice.", XP002170602, Database accession no. PREV199800035508 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; SCHULTZ J. ET AL: "Induction of long-lasting cytokine effect by injection of IL - 12 encoding plasmid DNA.", XP002170605, retrieved from STN Database accession no. 2001038439 *
EMI YASUNORI ET AL: "Interleukin-12 (IL-12) enhances antitumor activity of chemotherapy and radiotherapy in murine models.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 36, 1995, Eighty-sixth Annual Meeting of the American Association for Cancer Research;Toronto, Ontario, Canada; March 18-22, 1995, 1995, pages 480, XP002170599, ISSN: 0197-016X *
GENE THERAPY, vol. 3, no. 6, 1996, pages 542 - 548, ISSN: 0969-7128 *
GENE THERAPY, vol. 6, no. 4, April 1999 (1999-04-01), pages 606 - 615, ISSN: 0969-7128 *
HUMAN GENE THERAPY, vol. 10, no. 3, 10 February 1999 (1999-02-10), pages 407 - 417, ISSN: 1043-0342 *
HUMAN GENE THERAPY, vol. 11, no. 13, 1 September 2000 (2000-09-01), pages 1851 - 1862, ISSN: 1043-0342 *
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol. 20, no. 4, November 1998 (1998-11-01), pages 473 - 492, ISSN: 0892-3973 *
NESTLE FRANK O ET AL: "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.", NATURE MEDICINE, vol. 4, no. 3, March 1998 (1998-03-01), pages 328 - 332, XP002170598, ISSN: 1078-8956 *
SK MENDIRATTA ET AL: "Intratumoral delivery of iL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity", GENE THERAPY,GB,MACMILLAN PRESS LTD., BASINGSTOKE, vol. 6, no. 5, May 1999 (1999-05-01), pages 833 - 839, XP002118170, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
WO2001052874A9 (en) 2003-05-30
JP2003525222A (en) 2003-08-26
AU4050801A (en) 2001-07-31
WO2001052874A2 (en) 2001-07-26
DE60113805D1 (en) 2006-02-16
ES2246314T3 (en) 2006-02-16
ATE305801T1 (en) 2005-10-15
US20030118564A1 (en) 2003-06-26
EP1248654B1 (en) 2005-10-05
EP1248654A2 (en) 2002-10-16
US7141550B2 (en) 2006-11-28
DE60113805T2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2001052874A3 (en) Intra-tumoral administration of il-12 encoding nucleic acid molecules
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2001079443A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
HK1053985A1 (en) Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP2093298A3 (en) Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
WO2002014485A3 (en) Kallikrein gene
YU68702A (en) Novel lhrh-antagonists, production and use thereof as medicament
WO2002060923A3 (en) B-superfamily conotoxins
HK1048480A1 (en) Dna encoding human alpha1g-c t-type calcium channel
WO2001068676A3 (en) Lhrh-antagonists, production and use thereof as medicament
WO2003018535A3 (en) Novel aminobenzoephenones
WO2001003728A3 (en) Gene therapy for enhancing and/or inducing angiogenesis
WO2001057069A3 (en) Targeting peptides
WO2001053347A3 (en) Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
WO2001000784A3 (en) Compound derived from an offset orf of the ice gene
AU2001286687A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
AU2002232599A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001272910A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002074794A3 (en) Compositions useful in gene therapy
WO2002044379A3 (en) Transforming growth factor-beta-related molecules and uses thereof
WO2001016158A3 (en) Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor
AU2001263401A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 552921

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001911481

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001911481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10181794

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 2001911481

Country of ref document: EP